Posted by Michael Wonder on 15 Apr 2018
Hodgkin's patients have Keytruda cost cut
15 April 2018 - Patients with a form of Hodgkin lymphoma will have the cost of a breakthrough drug slashed by thousands from next month.
Keytruda would have cost $200,000 for each course of treatment but the federal government's move to list it on the Pharmaceutical Benefits Scheme means patients won't pay more than $39.50 a script.
Concession patients will pay $6.40.
